

J Janne Vehreschild

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5003588/publications.pdf>

Version: 2024-02-01

157
papers

8,770
citations

57758

44
h-index

48315

88
g-index

174
all docs

174
docs citations

174
times ranked

11310
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality). <i>Infection</i> , 2023, 51, 71-81.	4.7	1
2	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac029.	0.9	3
3	Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. <i>HIV Medicine</i> , 2022, 23, 895-910.	2.2	16
4	Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 182-192.	1.5	16
5	COVID-19 in cancer patients: clinical characteristics and outcome – an analysis of the LEOSS registry. <i>Annals of Hematology</i> , 2021, 100, 383-393.	1.8	127
6	Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients. <i>Medical Mycology</i> , 2021, 59, 93-101.	0.7	4
7	Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response. <i>BMC Infectious Diseases</i> , 2021, 21, 296.	2.9	24
8	Primary prophylaxis of bacterial infections and <i>Pneumocystis jirovecii</i> pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). <i>Annals of Hematology</i> , 2021, 100, 1603-1620.	1.8	39
9	Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. <i>BMC Cancer</i> , 2021, 21, 719.	2.6	10
10	Prediction of COVID-19 deterioration in high-risk patients at diagnosis: an early warning score for advanced COVID-19 developed by machine learning. <i>Infection</i> , 2021, , 1.	4.7	18
11	Development and validation of a simplified risk score for the prediction of critical COVID-19 illness in newly diagnosed patients. <i>Journal of Medical Virology</i> , 2021, 93, 6703-6713.	5.0	6
12	Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer. <i>European Journal of Cancer</i> , 2021, 155, 281-290.	2.8	4
13	Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. <i>Lancet HIV</i> , 2021, 8, e711-e722.	4.7	35
14	Clinical and pharmaco-economic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis. <i>Mycoses</i> , 2021, 64, 437-444.	4.0	2
15	First results of the Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS). <i>Infection</i> , 2021, 49, 63-73.	4.7	62
16	All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort. <i>Infection</i> , 2021, 50, 423.	4.7	6
17	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0258684.	2.5	5
18	Machine Learning Based Prediction of COVID-19 Mortality Suggests Repositioning of Anticancer Drug for Treating Severe Cases. <i>Artificial Intelligence in the Life Sciences</i> , 2021, 1, 100020.	2.2	6

#	ARTICLE	IF	CITATIONS
19	Systematic Review and Meta-analysis of Treatment Interruptions in Human Immunodeficiency Virus (HIV) Type 1â€“infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials. <i>Clinical Infectious Diseases</i> , 2020, 70, 1406-1417.	5.8	5
20	Clinical Impact of Rapid Species Identification From Positive Blood Cultures With Same-day Phenotypic Antimicrobial Susceptibility Testing on the Management and Outcome of Bloodstream Infections. <i>Clinical Infectious Diseases</i> , 2020, 70, 1285-1293.	5.8	29
21	Cervical cancer risk in women living with HIV across four continents: A multicohort study. <i>International Journal of Cancer</i> , 2020, 146, 601-609.	5.1	37
22	Association Between Prescribed Opioids and Infections in Patients With Neutropenia and Cancer. <i>JAMA Internal Medicine</i> , 2020, 180, 320.	5.1	2
23	Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001â€“2018. <i>Emerging Infectious Diseases</i> , 2020, 26, 2439-2443.	4.3	1
24	Design and evaluation of a data anonymization pipeline to promote Open Science on COVID-19. <i>Scientific Data</i> , 2020, 7, 435.	5.3	35
25	The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. <i>European Respiratory Journal</i> , 2020, 56, 2001494.	6.7	368
26	Rapid Uptake of Pre-Exposure Prophylaxis After Significant Price Reduction in Germany Highlights Importance of Pre-Exposure Prophylaxis Accessibility. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 721-733.	1.1	4
27	Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviralâ€“naïve persons starting treatment. <i>HIV Medicine</i> , 2020, 21, 599-606.	2.2	9
28	Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005â€“2017. <i>Infection</i> , 2020, 48, 723-733.	4.7	9
29	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. <i>Cell</i> , 2020, 180, 471-489.e22.	28.9	106
30	HEnRY: a DZIF LIMS tool for the collection and documentation of biomaterials in multicentre studies. <i>BMC Bioinformatics</i> , 2020, 21, 290.	2.6	2
31	Frequently asked questions regarding SARS-CoV-2 in cancer patientsâ€”recommendations for clinicians caring for patients with malignant diseases. <i>Leukemia</i> , 2020, 34, 1487-1494.	7.2	50
32	The German Corona Consensus Dataset (GECCO): a standardized dataset for COVID-19 research in university medicine and beyond. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 341.	3.0	54
33	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , 2020, 15, e0243625.	2.5	8
34	Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance of <i>Clostridiales</i> . <i>Gut Microbes</i> , 2019, 10, 133-141.	9.8	15
35	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3315-3327.	3.0	30
36	Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1200-1212.	6.0	167

#	ARTICLE	IF	CITATIONS
37	ECMM <i>Candi</i>Regâ€”A ready to use platform for outbreaks and epidemiological studies. <i>Mycoses</i> , 2019, 62, 920-927.	4.0	19
38	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	9.1	970
39	HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?. <i>Infection</i> , 2019, 47, 293-300.	4.7	6
40	Impact of single-room contact precautions on hospital-acquisition and transmission of multidrug-resistant <i>Escherichia coli</i> : a prospective multicentre cohort study in haematological and oncological wards. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1013-1020.	6.0	17
41	Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals. <i>International Journal of Infectious Diseases</i> , 2019, 83, 130-138.	3.3	10
42	The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 2647-2659.	1.1	6
43	2187. Prediction of Patient Outcome During Febrile Neutropenia Despite Anti-infective Treatment Using Machine Learning Algorithms. <i>Open Forum Infectious Diseases</i> , 2019, 6, S744-S744.	0.9	2
44	224. Epidemiology of Bloodstream infections in a Cohort of Allogeneic Hematopoietic Stem Cell Transplant Patients from 2009 to 2018. <i>Open Forum Infectious Diseases</i> , 2019, 6, S130-S130.	0.9	0
45	Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016. <i>Infection</i> , 2019, 47, 247-255.	4.7	9
46	Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016. <i>Journal of Hospital Infection</i> , 2019, 101, 339-346.	2.9	12
47	Prognostic factors in 264 adults with invasive <i>Scedosporium</i> spp. and <i>Lomentospora prolificans</i> infection reported in the literature and FungiScope^{Â®}. <i>Critical Reviews in Microbiology</i> , 2019, 45, 1-21.	6.1	106
48	Hotspots of Transmission Driving the Local Human Immunodeficiency Virus Epidemic in the Cologne-Bonn Region, Germany. <i>Clinical Infectious Diseases</i> , 2019, 68, 1539-1546.	5.8	11
49	Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. <i>Clinical Microbiology and Infection</i> , 2019, 25, 253.e1-253.e4.	6.0	9
50	Diagnostic work up to assess early response indicators in invasive pulmonary aspergillosis in adult patients with haematologic malignancies. <i>Mycoses</i> , 2019, 62, 486-493.	4.0	16
51	Pelvic cellulitis caused by <i>Raoultella planticola</i> in a neutropenic patient. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 298-301.	1.7	2
52	The Role of Microbiota in Preventing Multidrug-Resistant Bacterial Infections. <i>Deutsches A&#x0308;rztblatt International</i> , 2019, 116, 670-676.	0.9	8
53	Chlorhexidine-containing dressings in the prevention of central venous catheter-related bloodstream infections: A cost and resource utilization analysis. <i>American Journal of Infection Control</i> , 2018, 46, 992-997.	2.3	8
54	Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 31-49.	1.8	31

#	ARTICLE	IF	CITATIONS
55	Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 52-57.	2.4	17
56	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018, 24, 1701-1707.	30.7	195
57	Rapid detection of NDM, KPC and OXA-48 carbapenemases directly from positive blood cultures using a new multiplex immunochromatographic assay. <i>PLoS ONE</i> , 2018, 13, e0204157.	2.5	31
58	Azole-Resistance in <i>Aspergillus terreus</i> and Related Species: An Emerging Problem or a Rare Phenomenon?. <i>Frontiers in Microbiology</i> , 2018, 9, 516.	3.5	66
59	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (<sc>AGIHO</sc>). <i>Mycoses</i> , 2018, 61, 796-813.	4.0	69
60	Epidemiology of Surgical Site Infections With <i>Staphylococcus aureus</i> in Europe: Protocol for a Retrospective, Multicenter Study. <i>JMIR Research Protocols</i> , 2018, 7, e63.	1.0	13
61	Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis. <i>European Radiology</i> , 2017, 27, 3275-3282.	4.5	34
62	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. <i>Lancet HIV</i> , 2017, 4, e349-e356.	4.7	805
63	Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany. <i>Epidemiology and Infection</i> , 2017, 145, 236-244.	2.1	12
64	Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2017, 96, 1775-1792.	1.8	129
65	FungiScope™ Global Emerging Fungal Infection Registry. <i>Mycoses</i> , 2017, 60, 508-516.	4.0	47
66	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 1571-1577.	5.8	52
67	Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3- ¹² -D-glucan, <i>Aspergillus</i> PCR, multifungal DNA-microarray, and <i>Aspergillus</i> azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. <i>Clinical Microbiology and Infection</i> , 2016, 22, 862-868.	6.0	78
68	A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2634-2641.	3.0	49
69	Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2957-2963.	3.0	88
70	Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. <i>Annals of Hematology</i> , 2016, 95, 1435-1455.	1.8	169
71	Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. <i>Oncotarget</i> , 2016, 5, e1150399.	4.6	94
72	Domestic mould exposure and invasive aspergillosis – air sampling of <i>Aspergillus</i> spp. spores in homes of hematological patients, a pilot study. <i>Medical Mycology</i> , 2016, 54, 576-583.	0.7	13

#	ARTICLE	IF	CITATIONS
73	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	9.1	528
74	Identification of invasive fungal diseases in immunocompromised patients by combining an <i>Aspergillus</i> specific PCR with a multifungal DNA microarray from primary clinical samples. <i>Mycoses</i> , 2015, 58, 735-745.	4.0	30
75	Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy. <i>The Cochrane Library</i> , 2015, , CD007107.	2.8	13
76	Fungus-Specific CD4 ⁺ T Cells for Rapid Identification of Invasive Pulmonary Mold Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 348-352.	5.6	47
77	A cost and resource utilization analysis of micafungin bridging for hematological high-risk patients undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2015, 94, 526-531.	2.2	8
78	Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 331-338.	2.9	25
79	Our 2015 approach to invasive pulmonary aspergillosis. <i>Mycoses</i> , 2015, 58, 375-382.	4.0	26
80	Economic burden of <i>Clostridium difficile</i> associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. <i>Infection</i> , 2015, 43, 707-714.	4.7	42
81	Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics. <i>Pharmaceutical Research</i> , 2015, 32, 2029-2037.	3.5	13
82	Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. <i>British Journal of Haematology</i> , 2015, 168, 806-810.	2.5	53
83	Clinical course and quality of care in ART-naïve patients newly presenting in a HIV outpatient clinic. <i>Infection</i> , 2014, 42, 849-857.	4.7	8
84	PTX3 Deficiency and Aspergillosis. <i>New England Journal of Medicine</i> , 2014, 370, 1665-1667.	27.0	7
85	Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: A 6-yr analysis from the cologne cohort for neutropenic patients. <i>European Journal of Haematology</i> , 2014, 93, 400-406.	2.2	16
86	Treatment cost development of patients undergoing remission induction chemotherapy: a pharmaco-economic analysis before and after introduction of posaconazole prophylaxis. <i>Mycoses</i> , 2014, 57, 90-97.	4.0	13
87	Low-grade proteinuria is highly prevalent in HIV-positive patients on antiretroviral treatment. <i>Aids</i> , 2014, 28, 1783-1789.	2.2	23
88	Different doses of micafungin for prophylaxis of invasive fungal diseases in hematological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany. <i>Transplant Infectious Disease</i> , 2014, 16, 968-974.	1.7	9
89	<i>Clostridium Difficile</i> Infection in Patients with Acute Myelogenous Leukemia and in Patients Undergoing Allogeneic Stem Cell Transplantation: Epidemiology and Risk Factor Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 823-828.	2.0	47
90	Causes of death in HIV-infected patients from the Cologne "Bonn cohort. <i>Infection</i> , 2014, 42, 135-140.	4.7	42

#	ARTICLE	IF	CITATIONS
91	Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Oncology</i> , 2014, 25, 1709-1718.	1.2	34
92	A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3387-3392.	3.0	84
93	Estimating site costs prior to conducting clinical trials. <i>Clinical Investigation</i> , 2014, 4, 227-234.	0.0	9
94	As Galactomannan Disappoints, Our Quest for a Feasible Diagnostic Standard for Invasive Aspergillosis Continues. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 248-249.	5.6	8
95	Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScope, ©): Case Matched Analysis. <i>Blood</i> , 2014, 124, 1151-1151.	1.4	1
96	Evaluation of an infectious disease consultation programme in a German tertiary care hospital. <i>Infection</i> , 2013, 41, 1121-1128.	4.7	17
97	Intracellular concentrations of anidulafungin in different compartments of the peripheral blood. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 379-382.	2.5	7
98	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. <i>Haematologica</i> , 2013, 98, e127-e130.	3.5	99
99	Pneumonia and Lung Infiltrates in Neutropenic Patients: Many Stones Unturned. <i>Annals of the American Thoracic Society</i> , 2013, 10, 493-495.	3.2	3
100	Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Oncology</i> , 2013, 24, 1189-1202.	1.2	29
101	Mucormycosis treated with posaconazole: review of 96 case reports. <i>Critical Reviews in Microbiology</i> , 2013, 39, 310-324.	6.1	127
102	Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1664-1671.	3.2	44
103	Pharmacokinetics of Different Dosing Strategies of Oral Posaconazole in Patients with Compromised Gastrointestinal Function and Who Are at High Risk for Invasive Fungal Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2652-2658.	3.2	39
104	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012, 41, 1807-1820.	1.9	34
105	Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2260-2267.	3.0	85
106	Pandemic 2009 influenza A(H1N1) virus infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. <i>Epidemiology and Infection</i> , 2012, 140, 1848-1852.	2.1	29
107	Liver involvement in HIV-infected patients diagnosed with syphilis. <i>Infection</i> , 2012, 40, 543-547.	4.7	17
108	Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. <i>Infection</i> , 2012, 40, 613-619.	4.7	118

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 130-134.	2.5	22
110	Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 228-231.	2.5	10
111	Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 987-995.	1.9	45
112	Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an <i>Aspergillus</i> PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. <i>European Journal of Haematology</i> , 2012, 89, 120-127.	2.2	63
113	Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. <i>Eurosurveillance</i> , 2012, 17, .	7.0	38
114	Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. <i>Eurosurveillance</i> , 2012, 17, 20262.	7.0	15
115	Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. <i>Haematologica</i> , 2011, 96, 1855-1860.	3.5	22
116	Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. <i>Mycoses</i> , 2011, 54, 230-233.	4.0	6
117	Current issues in the clinical management of invasive candida infections – the AGIHO, DMycG, A–GMM and PEG web-based survey and expert consensus conference 2009. <i>Mycoses</i> , 2011, 54, e546-56.	4.0	11
118	Current issues in the clinical management of invasive aspergillosis – the AGIHO, DMycG, A–GMM and PEG web-based survey and expert consensus conference 2009. <i>Mycoses</i> , 2011, 54, e557-68.	4.0	13
119	Making Moulds Meet Information retrieval as a basis for understanding <i>Pseudallescheria</i> and <i>Scedosporium</i> . <i>Mycoses</i> , 2011, 54, 1-4.	4.0	3
120	Environmental and clinical epidemiology of <i>Aspergillus terreus</i> : data from a prospective surveillance study. <i>Journal of Hospital Infection</i> , 2011, 78, 226-230.	2.9	31
121	Therapeutic Drug Monitoring of Voriconazole and Posaconazole. <i>Pharmacotherapy</i> , 2011, 31, 214-225.	2.6	58
122	Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT. <i>Supportive Care in Cancer</i> , 2011, 19, 1211-1216.	2.2	10
123	Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5798-5803.	3.2	80
124	Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 95-113.	1.8	12
125	Intracellular Concentrations of Posaconazole in Different Compartments of Peripheral Blood. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2928-2931.	3.2	43
126	Causes of Death in HIV-1 Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies. <i>Clinical Infectious Diseases</i> , 2010, 50, 1387-1396.	5.8	525

#	ARTICLE	IF	CITATIONS
127	Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 207-212.	3.2	70
128	Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1466-1471.	3.0	106
129	Forty-one recent cases of invasive zygomycosis from a global clinical registry. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 296-302.	3.0	169
130	Quantitation of Azoles and Echinocandins in Compartments of Peripheral Blood by Liquid Chromatography-Tandem Mass Spectrometry. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1815-1819.	3.2	76
131	Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome – still an open question?. <i>Leukemia and Lymphoma</i> , 2010, 51, 20-26.	1.3	7
132	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study. <i>Lancet</i> , The, 2010, 376, 340-345.	13.7	82
133	Dose Escalation of Caspofungin for Invasive Aspergillosis - A Phase II Trial. <i>Blood</i> , 2010, 116, 2309-2309.	1.4	0
134	Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Haematologica</i> , 2009, 94, 113-122.	3.5	160
135	Invasive candidiasis and candidemia: from current opinions to future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 735-748.	4.1	31
136	Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. <i>Annals of Hematology</i> , 2009, 88, 121-132.	1.8	51
137	Treatment of invasive candidiasis with echinocandins. <i>Mycoses</i> , 2009, 52, 476-486.	4.0	21
138	Current experience in treating invasive zygomycosis with posaconazole. <i>Clinical Microbiology and Infection</i> , 2009, 15, 77-81.	6.0	44
139	Low prevalence of human metapneumovirus and human bocavirus in adult immunocompromised high risk patients suspected to suffer from <i>Pneumocystis pneumonia</i> . <i>Journal of Infection</i> , 2009, 58, 227-231.	3.3	23
140	Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 446-450.	2.5	31
141	Antifungal Prophylaxis in Haematology. , 2009, , 449-457.		0
142	Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. <i>International Journal of Hematology</i> , 2008, 87, 126-131.	1.6	13
143	Antifungal treatment strategies in high risk patients. <i>Mycoses</i> , 2008, 51, 46-51.	4.0	31
144	Patients at High Risk of Invasive Fungal Infections. <i>Drugs</i> , 2008, 68, 1941-1962.	10.9	210

#	ARTICLE	IF	CITATIONS
145	Fungiscope - the Global Database for Rare Fungal Infections. <i>International Journal of Infectious Diseases</i> , 2008, 12, e283.	3.3	0
146	Anidulafungin: advantage for the newcomer?. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 207-216.	3.1	4
147	Posaconazole concentrations in the central nervous system. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1468-1470.	3.0	68
148	Posaconazole: a next-generation triazole antifungal. <i>Future Microbiology</i> , 2007, 2, 231-243.	2.0	36
149	A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). <i>Journal of Infection</i> , 2007, 55, 445-449.	3.3	93
150	Anidulafungin ? state of affairs from a clinical perspective. <i>Mycoses</i> , 2007, 50, 38-43.	4.0	15
151	Zygomycosis ? current epidemiological aspects. <i>Mycoses</i> , 2007, 50, 50-55.	4.0	24
152	Severe Pneumonia and Human Bocavirus in Adult. <i>Emerging Infectious Diseases</i> , 2006, 12, 1614-1616.	4.3	91
153	Is there a role for polyenes in treating invasive mycoses?. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 565-570.	3.1	16
154	Organmykosen auf einen Blick: Diagnostik und Therapie lebensbedrohlicher Pilzinfektionen. <i>Mycoses</i> , 2006, 49, 155-156.	4.0	0
155	Salvage Therapy of Refractory Chronic Disseminated Candidiasis in a Patient with Acute Myeloid Leukaemia and Secondary Prophylaxis During Allogeneic Stem Cell Transplantation. <i>Mycoses</i> , 2006, 49, 42-47.	4.0	10
156	Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. <i>Future Microbiology</i> , 2006, 1, 161-170.	2.0	14
157	Neutropenia. , 0, , 143-196.		0